0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
JAMA Patient Page |

PCSK9 Inhibitors for Treating High Cholesterol FREE

Jill Jin, MD, MPH
JAMA. 2015;314(21):2320. doi:10.1001/jama.2015.13748.
Text Size: A A A
Published online

PCSK9 inhibitors are a new type of cholesterol-lowering medication available in the United States.

CHOLESTEROL AND CARDIOVASCULAR DISEASE

Several types of cholesterol occur in the bloodstream, the most important of which are low-density lipoprotein (“bad”) cholesterol (LDL-C) and high-density lipoprotein (“good”) cholesterol (HDL-C). Having high cholesterol generally refers to having high LDL-C levels. Having high LDL-C increases the risk of having plaque buildup inside blood vessels, a condition called atherosclerosis. When atherosclerosis occurs in the blood vessels of the heart or brain, it can lead to heart attacks and strokes, 2 forms of cardiovascular disease. Cardiovascular disease is currently the leading cause of death in the United States.

Lowering cholesterol with both lifestyle changes and medications helps lower the risk of developing and dying of cardiovascular disease. In some people, a healthy diet and regular exercise are enough; others require medications. The most common drugs used to lower cholesterol are statins, but in some people with high cholesterol, statins do not lower cholesterol levels enough. Others cannot take statins because of side effects such as muscle pain or liver problems.

PCSK9 INHIBITORS: A NEW TREATMENT

PCSK9 inhibitors are monoclonal antibodies, proteins designed and created in a laboratory to recognize and attach to another protein. PCSK9 inhibitors target a protein called PCSK9 that raises LDL-C levels. When a PCSK9 inhibitor attaches to a PCSK9 protein, it stops the PCSK9 protein from working, which leads to lower LDL-C.

Clinical trials have shown that PCSK9 inhibitors are powerful in reducing LDL-C levels. Three studies published in April 2015 showed that in patients taking standard statin cholesterol-lowering treatment, adding PCSK9 inhibitors further reduced LDL-C by about 60%. There are 2 PCSK9 inhibitors currently approved in the United States by the US Food and Drug Administration: alirocumab and evolocumab. They are injected under the skin every 2 to 4 weeks and are not available as an oral pill. They are significantly more expensive than other cholesterol medications.

There are very limited uses for these new drugs. PCSK9 inhibitors can be used together with statins in people with cardiovascular disease and a very high risk of stroke or heart attack who do not reach their goal LDL-C levels with statins alone. Or they can be used instead of statins in people who have major side effects from statins. They can also be used in people with very high LDL-C levels due to a genetic condition called familial hypercholesterolemia.

FUTURE DIRECTIONS

Although lowering LDL-C levels is good, an important question is whether PCSK9 inhibitors improve cardiovascular disease outcomes; that is, if they lower the rates of heart attacks and strokes and prevent the development of heart failure. So far, there is no clinical evidence that this is the case. Trials focusing specifically on long-term cardiovascular outcomes and safety are under way, and the results of these trials in the next several years will be very important in determining whether PCSK9 inhibitors become a more common part of the regimen for treating high cholesterol.

Box Section Ref ID

For More Information

To find this and previous JAMA Patient Pages, go to the Patient Page link on JAMA’s website at www.jama.com. Spanish translations are available in the supplemental content tab.

ARTICLE INFORMATION

The JAMA Patient Page is a public service of JAMA. The information and recommendations appearing on this page are appropriate in most instances, but they are not a substitute for medical diagnosis. For specific information concerning your personal medical condition, JAMA suggests that you consult your physician. This page may be photocopied noncommercially by physicians and other health care professionals to share with patients. To purchase bulk reprints, call 312/464-0776.

Sources: Evolocumab [From the Medical Letter]. JAMA. doi:10.1001/jama.2015.14772.

Sullivan D, Olsson AG, Scott R, et al. JAMA. 2012;308(23):2497-2506.

Shrank WH, Barlow JF, Brennan TA. JAMA. 2015;314(14):1443-1444.

Stein EA, Raal FJ. Curr Cardiol Rep. 2015;17(11):104.

Topic: Cardiovascular Disease

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Spanish Patient Page: Inhibidores de PCSK9 para tratar el colesterol alto

Supplemental Content

Some tools below are only available to our subscribers or users with an online account.

12,138 Views
0 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Jobs